Keros Therapeutics (KROS) Cash & Equivalents (2019 - 2025)

Keros Therapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $287.4 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 48.67% year-over-year to $287.4 million; the trailing twelve-month figure through Dec 2025 stood at $287.4 million (down 48.67% YoY), and the FY2025 full-year result was $287.4 million, down 48.67% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $287.4 million, down from $693.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $720.5 million in Q1 2025, with the low at $215.6 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $376.5 million across 5 years, with a median of $305.0 million in 2023.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 368.11% — and 2025, when it sank 48.67%.
• Keros Therapeutics' Cash & Equivalents stood at $230.0 million in 2021, then increased by 21.3% to $279.0 million in 2022, then climbed by 18.67% to $331.1 million in 2023, then soared by 69.09% to $559.9 million in 2024, then slumped by 48.67% to $287.4 million in 2025.
• The last three Cash & Equivalents figures came in at $287.4 million (Q4 2025), $693.5 million (Q3 2025), and $690.2 million (Q2 2025), per Business Quant data.